Google
KPRX — KIORA PHARMACEUTICALS INC (Healthcare >> Biotechnology)
KPRX FAQ
What is KPRX's P/E ratio?
KIORA PHARMACEUTICALS INC (KPRX) currently trades at a P/E ratio of 428.88.
What is KPRX's ROE?
KIORA PHARMACEUTICALS INC reports a Return on Equity (ROE) of -79.37%.
What is KPRX's dividend yield?
KIORA PHARMACEUTICALS INC offers a dividend yield of 0.00%.
What is KPRX's Deepscope Quality Score?
Deepscope rates KPRX's overall financial quality at 8 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy KPRX?
Deepscope's AI Timing Score for KPRX is 91 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does KPRX belong to?
KIORA PHARMACEUTICALS INC is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.
|
USD 2.50
Price
-0.13
(-4.94%)
Day Change
|
|
|---|
KPRX, the overall quality is not good ( Quality = 8) but the timing to buy is ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
P/E ratio is relatively high
ROE is relatively low.
ROA is relatively low.
Acceleration of ROE growth rate is below our criteria.
Historical ROE is relatively low
Negative growth of ROE in the last year.
ROE is decreasing significantly
ROA is too relatively low compare to ROE
Acceleration of ROA growth rate is below our criteria.
Growth of ROA was below our criteria in the last year.
Current growth of ROA was below our criteria.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not good , financial health is not good , and ability to make profit is not quite good , ...
| Quality Factors |
|
42% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 82 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 2.50 |
| PBV / Sector |
0.83 / 4.63
GREAT
|
| Earning Per Share | -2.41 |
| PE / Sector |
428.88 / 17.43
|
| PEG or PE/Growth / Sector |
-2.67 / 0.53
|
| Average 1M Daily Value |
0.12 M
GREAT
|
| Average 1W Daily Value |
0.06 M
GREAT
|
| Timing Factors |
|
42% |
| Financial Health |
|
45% |
| Ability to Make Profit |
|
56% |
| Return to Investors |
|
4% |
| Registration Details |
| Analyze Date | 2026-06-06 09:08:48 |
| Symbol | KPRX |
| Name | KIORA PHARMACEUTICALS INC |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 4.43 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 11.50 / 8,857.28 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 332 Encinitas Boulevard, Encinitas, CA, United States, 92024
Phone: 858 224 9600
Website: https://www.kiorapharma.com
Sector: Healthcare >> Biotechnology
Description: Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, engages in the development and commercialization of therapies for the treatment of ophthalmic diseases. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 2 clinical trials for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. The company is also developing KIO-104, a non-steroidal, immuno-modulatory, small-molecule inhibitor of dihydroorotate dehydrogenase, which is in phase 1b/2a study for the treatment of posterior non-infectious uveitis, as well as under pre-clinical development for the treatment of proliferative vitreoretinopathy; and KIO-101, an eye drop formulation for the treatment of ocular presentation of rheumatoid arthritis. It has a strategic development and commercialization agreement with Théa Open Innovation for the development of KIO-301. The company operates in the United States, Austria, and Australia. The company was formerly known as Eyegate Pharmaceuticals, Inc. and changed its name to Kiora Pharmaceuticals, Inc. in November 2021. Kiora Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Encinitas, California.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
